Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant

View ORCID ProfileVenkata Viswanadh Edara, Katharine Floyd, Lilin Lai, View ORCID ProfileMeredith Gardner, William Hudson, View ORCID ProfileAnne Piantadosi, View ORCID ProfileJesse J. Waggoner, View ORCID ProfileAhmed Babiker, View ORCID ProfileRafi Ahmed, Xuping Xie, Kumari Lokugamage, View ORCID ProfileVineet Menachery, Pei-Yong Shi, View ORCID ProfileMehul S. Suthar, for the COVID-19 Neutralization Study Group
doi: https://doi.org/10.1101/2021.02.02.21250799
Venkata Viswanadh Edara
1Emory University School of Medicine, Atlanta, GA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Venkata Viswanadh Edara
Katharine Floyd
1Emory University School of Medicine, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lilin Lai
1Emory University School of Medicine, Atlanta, GA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meredith Gardner
1Emory University School of Medicine, Atlanta, GA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meredith Gardner
William Hudson
1Emory University School of Medicine, Atlanta, GA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Piantadosi
1Emory University School of Medicine, Atlanta, GA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne Piantadosi
Jesse J. Waggoner
1Emory University School of Medicine, Atlanta, GA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jesse J. Waggoner
Ahmed Babiker
1Emory University School of Medicine, Atlanta, GA
M.B.B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ahmed Babiker
Rafi Ahmed
1Emory University School of Medicine, Atlanta, GA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rafi Ahmed
Xuping Xie
2University of Texas Medical Branch, Galveston, TX
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumari Lokugamage
2University of Texas Medical Branch, Galveston, TX
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vineet Menachery
2University of Texas Medical Branch, Galveston, TX
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vineet Menachery
Pei-Yong Shi
2University of Texas Medical Branch, Galveston, TX
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehul S. Suthar
1Emory University School of Medicine, Atlanta, GA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mehul S. Suthar
  • For correspondence: mehul.s.suthar@emory.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS-CoV-2 infection and can last for several months. Similarly, the messenger RNA vaccine, mRNA-1273, generates serum neutralizing antibodies that are detected through at least day 119. However, the recent emergence of the B.1.1.7 variant has raised significant concerns about the breadth of these neutralizing antibody responses. In this study, we used a live virus neutralization assay to compare the neutralization potency of sera from infected and vaccinated individuals against a panel of SARS-CoV-2 variants, including SARS-CoV-2 B.1.1.7. We found that both infection- and vaccine-induced antibodies were effective at neutralizing the SARS-CoV-2 B.1.1.7 variant. These findings support the notion that in the context of the UK variant, vaccine-induced immunity can provide protection against COVID-19. As additional SARS-CoV-2 viral variants continue to emerge, it is crucial to monitor their impact on neutralizing antibody responses following infection and vaccination.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported in part by grants (NIH P51 OD011132, 3U19AI057266-17S1, U19AI090023, R01AI127799, R01AI148378, K99AI153736, and UM1AI148684 to Emory University; and R00AG049092 and R24AI120942 to University of Texas Medical Branch) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), by the Emory Executive Vice President for Health Affairs Synergy Fund award, the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Childrens Healthcare of Atlanta, COVID-Catalyst-I3 Funds from the Woodruff Health Sciences Center and Emory School of Medicine, Woodruff Health Sciences Center 2020 COVID-19 CURE Award, and the Vital Projects/Proteus funds. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

For samples collected at Emory University, collection and processing were performed under approval from the University Institutional Review Board (IRB #00001080 and #00022371). Adults ≥18 years were enrolled who met eligibility criteria for SARS-CoV-2 infection (PCR confirmed by a commercially available assay) and provided informed consent. For the mRNA-1273 phase 1 clinical trial, the neutralization assays were conducted on deidentified specimens, as protocol-defined research. The mRNA-1273 phase 1 clinical trial (NCT04283461) was reviewed and approved by the Advarra institutional review board, which functioned as a single board. The trial was overseen by an independent safety monitoring committee. All participants provided written informed consent before enrollment. The trial was conducted under an Investigational New Drug application submitted to the Food and Drug Administration. The NIAID served as the trial sponsor and made all decisions regarding the study design and implementation.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* The COVID-19 Neutralization Study Group members are listed at the end of the manuscript text.

Data Availability

The datasets generated during and/or analyzed in the current study are available from the corresponding author on reasonable request following acceptance in a peer-reviewed journal.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant
Venkata Viswanadh Edara, Katharine Floyd, Lilin Lai, Meredith Gardner, William Hudson, Anne Piantadosi, Jesse J. Waggoner, Ahmed Babiker, Rafi Ahmed, Xuping Xie, Kumari Lokugamage, Vineet Menachery, Pei-Yong Shi, Mehul S. Suthar, for the COVID-19 Neutralization Study Group
medRxiv 2021.02.02.21250799; doi: https://doi.org/10.1101/2021.02.02.21250799
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant
Venkata Viswanadh Edara, Katharine Floyd, Lilin Lai, Meredith Gardner, William Hudson, Anne Piantadosi, Jesse J. Waggoner, Ahmed Babiker, Rafi Ahmed, Xuping Xie, Kumari Lokugamage, Vineet Menachery, Pei-Yong Shi, Mehul S. Suthar, for the COVID-19 Neutralization Study Group
medRxiv 2021.02.02.21250799; doi: https://doi.org/10.1101/2021.02.02.21250799

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)